DOI:

Thirty-day outcomes after TAVI in patients with severe aortic stenosis and moderate or severe mitral regurgitation

Baumgartner H. on behalf of the SOURCE XT Investigators

Transcatheter therapies in patients with mitral regurgitation or poor left ventricular function

Thirty-day outcomes after TAVI in patients with severe aortic stenosis and moderate or severe mitral regurgitation

Aims: Moderate and severe mitral regurgitation (MR) is associated with higher mortality in patients with CHF, but little is known about its impact on outcomes in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation (TAVI). Isolated surgical aortic valve replacement usually has a positive impact on functional MR but the effect of TAVI is not well understood. We sought to assess the effect of MR on early clinical outcomes after transcatheter SAPIEN XT valve (Edwards Lifesciences LLC, Irvine, CA, USA) implantation, and the impact of TAVR on MR.

Methods and results: SOURCE XT is a multicentre, prospective, post-approval study which enrolled >2,600 consecutive patients at 94 sites in 17 countries. Total of 968 patients (36.8%) did not have any MR at baseline, 1,144 patients (43.5%) were with mild MR, 461 patients (17.5%) were with moderate MR, and 56 patients (2.1%) were with severe MR. Patients with moderate or severe MR were included in the MR Group (MR-Gr, n=517) and those with none or mild MR were included in the control group (C-Gr, n=2,112). Compared to the C-Gr, patients in the MR-Gr were more likely to be older (82.3±5.4 vs. 81.6±5.9, p=0.0148), female (63.1% vs. 56.5%, p=0.0073) with NYHA III/IV (81.4 vs. 75.9%, p=0.0073) and greater STS score (10±8.3 vs. 8.1±6.6, p<0.0001). MR-Gr patients had significantly higher incidence of CHF, atrial fibrillation or renal insufficiency. Mean gradient was similar for the two groups (47.5±17.0 vs. 47.3±20.1 mmHg, p=0.81); however, EF was significantly lower (50.1±12.0% vs. 53.0±11.2%, p<0.0001) and pulmonary pressure was significantly higher (50.5±16.0 mmHg vs. 43.3±14.1 mmHg, p<0.0001) in MR-Gr vs. C-Gr. There were no significant differences between MR-Gr and C-Gr in terms of overall mortality (7.2% vs. 5.9%, p=0.28), cardiac death (2.5% vs. 2.2%, p=0.64), stroke (1.2% vs. 2.6%, p=0.0627), major vascular complications (1.4% vs. 1.9%, p=0.41) or major bleeding events (7.4% vs. 7.8%, p=0.81). One month after TAVI, MR had improved by at least 1 degree in 30.4% of patients with any MR at baseline and in 44% of patients with moderate or severe MR.

Conclusions: Despite significant comorbidity, TAVI in patients with severe aortic stenosis and concomitant moderate or severe MR was not associated with an increased mortality. Furthermore, MR was improved in 44% of patients but longer follow-up is needed to understand the potential benefit of TAVI in this subset of patients.

Volume 8 Supplement Q
Sep 30, 2012
Volume 8 Supplement Q
View full issue


Key metrics

On the same subject

Editorial

10.4244/EIJ-E-23-00052 Mar 18, 2024
Comparative preclinical assessment of drug-coated balloons: a blessing and a curse for clinical translation
Joner M and Wild L
free

Debate

10.4244/EIJ-E-24-00005 Mar 18, 2024
Ischaemic and viability testing for guiding PCI are overrated: pros and cons
McEntegart M et al
free

Original Research

10.4244/EIJ-D-23-00783 Mar 18, 2024
Redo-TAVI with the ACURATE neo2 and Prime XL for balloon-expandable transcatheter heart valve failure
Meier D et al
Trending articles
281.53

State-of-the-Art Review

10.4244/EIJ-D-21-00695 Nov 19, 2021
Transcatheter treatment for tricuspid valve disease
Praz F et al
free
243.2

State of the art

10.4244/EIJ-D-21-01117 Sep 20, 2022
Recanalisation of coronary chronic total occlusions
Di Mario C et al
free
208.35

State-of-the-Art Review

10.4244/EIJ-D-21-01034 Jun 3, 2022
Management of in-stent restenosis
Alfonso F et al
free
168.7

Translational research

10.4244/EIJ-D-21-00824 May 15, 2022
Bench test and in vivo evaluation of longitudinal stent deformation during proximal optimisation
Toth GG et al
free
167.05

Expert review

10.4244/EIJ-D-21-00690 May 15, 2022
Crush techniques for percutaneous coronary intervention of bifurcation lesions
Moroni F et al
free
151.03

State-of-the-Art

10.4244/EIJ-D-22-00776 Apr 3, 2023
Computed tomographic angiography in coronary artery disease
Serruys PW et al
free
118

Translational research

10.4244/EIJ-D-22-00718 Jun 5, 2023
Preclinical evaluation of the degradation kinetics of third-generation resorbable magnesium scaffolds
Seguchi M et al
110.35

Viewpoint

10.4244/EIJ-E-22-00007 May 15, 2022
TAVI at 20: how a crazy idea led to a clinical revolution
Eltchaninoff H et al
free
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 6.2
2022 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2023)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2024 Europa Group - All rights reserved